Clinical and Translational Research
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2022; 10(22): 7674-7685
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7674
Network pharmacology and molecular docking reveal zedoary turmeric-trisomes in Inflammatory bowel disease with intestinal fibrosis
Lie Zheng, Yong-Yi Ji, Yan-Cheng Dai, Xin-Li Wen, Shi-Cheng Wu
Lie Zheng, Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an 730000, Shaanxi Province, China
Yong-Yi Ji, Department of Neurology, Xi’an Hospital of Traditional Chinese Medicine, Xi’an 710021, Shaanxi Province, China
Yan-Cheng Dai, Department of Gastroenterology, Shanghai Traditional Chinese Medicine Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
Xin-Li Wen, Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, Xi’an 710003, Shaanxi Province, China
Shi-Cheng Wu, Department of Proctology, Gansu Academy of Traditional Chinese Medicine, GanSu Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu Province, China
Author contributions: Zheng L, Ji YY, Dai YC and Wu SC reviewed the literature and prepared the manuscript, performed to the writing and revising of the manuscript; Zheng L and Wen XL contributed to design this work, and performed overall supervision; Zheng L wrote and revised the paper; all authors approved the final manuscript.
Supported by General Research of Xi’an Science and Technology Planning Project, No. 2022JH-YBYJ-0265; Shaanxi Province Natural Science Basic Research Program-General Project, No: 2019JM-580 and 2021SF-314; Project of Shaanxi Administration of Traditional Chinese Medicine, No. 2019-ZZ-JC010; and Shaanxi Provincial Hospital of Traditional Chinese Medicine, No. 2021-07, 2018-04.
Institutional review board statement: Since this article is a molecular mechanism study of network pharmacology and does not involve animal experiments or clinical experiments, it does not require the approval of an ethics committee.
Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shi-Cheng Wu, Department of Proctology, Gansu Academy of Traditional Chinese Medicine, Gansu Hospital of Traditional Chinese Medicine, No. 418 Guazhou Road, Qilihe District, Lanzhou 730050, Gansu Province, China. 594068860@qq.com
Received: March 16, 2022
Peer-review started: March 16, 2022
First decision: April 11, 2022
Revised: May 5, 2022
Accepted: June 30, 2022
Article in press: June 30, 2022
Published online: August 6, 2022
Processing time: 127 Days and 20.4 Hours
Core Tip

Core Tip: Intestinal fibrosis is one of the common complications of inflammatory bowel disease (IBD). Finding effective drug treatment is an important issue that needs to be solved at the moment. The mechanism of zedoary turmeric-trisomes in the treatment of IBD with intestinal fibrosis can be predicted through network pharmacology and molecular docking, so as to provide theoretical reference for it to better play its therapeutic role.